Immunohistochemical Demonstration with Antibromodeoxyuridine Monoclonal Antibody in Experimental Meningeal Carcinomatosis Model

腦膜癌病腫瘤因惡性腦瘤和癌症治療法的進步而日益增加，對於此症目前尚無確立有效之治療法。本實驗以Walker 256 carcinosarcoma cells 注入大白鼠大池內作成實驗腦膜癌病之模型，利用抗溴脫氧尿核甘(BrdU)單一同本生物抗體能於細胞合成期將被細胞核撮入之溴脫氧連核甘(BrdU)以免疫組織化學ABC染色法標識之特性求其標識率(LI)，作為腫瘤細胞增殖能動態的檢討。其結果是以1*10000腫瘤細胞注入後，LI並非恆常，第一至第三日為較低之百分之十幾，其後LI漸增加，於注入後第七至第九日達最高之百分之四十幾，於注入後第十日腫瘤細胞中出現壞死現象，LI有低下之傾向。實驗腦膜癌病模型的生理病理形態和人體之惡性軟腦膜腫瘤相似，因此，我們建議針對包括腦膜癌病在內之惡性軟腦膜腫瘤，應於腫細胞增殖能開始增強而未其最高峰之前，開始化學療法，利用此染色法除能制定治療方式外並能當成抗癌劑效果判定之根據。

關鍵字

無資料

並列摘要

The usefulness of immunohistochemical demonstration with anti-bromodeoxyuridine (BrdU) monoclonal antibody for estimating proliferativve actibity was evaluated in experimental meningeal carcinomatosis model. The experimental model was developed by inoculation of 1*10000 Walker 256 carcinosarcoma cells into the cisterna magna of female Wistar rats. Every consecutive day after tumor inoculation, the rat was perfused by saline and then sacrificed 30 min after intravenous BrdU (200mg/Kg) injection. The brainwas removed, fixed in 80% ethanol and embedded in paraffin. Coronal sections of the brain 6 µ in thickness were obtained and stained immunohistochemically using the indirect immunoperoxidase (ABC) method with antiBrdU monoclonal antibody (Becton-Dickinson). The sections were counterstained by hematoxylin. Labeling index (LI) which represented the percentage of tumor cells in synthetic phase was obtained by counting immunoreactive cells under the microscope. LI was as low as 10.8% to 16.9% in the first 3 days after tumor inoculation. Four to 6 days after tumor inoculation when tumor cells grew several layers in the subarachnoid space, LI was 24.0% to 40.1%. LI increased to reach a plateau around 40.7% to 48.2%, 7 to 9 days after tumor inoculation. The days after inoculation when necrosis appeared in the tumor, BrdU-positive cells declinded and LI was between 29.1% to 35.0%. It is a useful method to estimate the proliferative activity of the experimental brain tumors, design treatment modalities and evaluate the effect of chemotherapeutic agents by using immunohistochemical demonstration with anti-BrdU monoclonal antibody. Therefore, we suggest that chemotherapy against malignant leptomeningeal tumors shall be carried out in early or intermediate stage before the proliferative activity reaches in plateau stage.

並列關鍵字

bromodeoxyuridine ； labeling index ； meningeal carcinomatosis

國際替代計量

Immunohistochemical Demonstration with Antibromodeoxyuridine Monoclonal Antibody in Experimental Meningeal Carcinomatosis Model

全文下載

主題瀏覽